Literature DB >> 23270679

[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].

B Duchemann1, B Duchemain, S Wong, V Baruch-Hennequin, S Rivera, L Quero, C Hennequin.   

Abstract

A 61-year-old man, with a tuberous sclerosis, experienced severe acute reactions during a concomitant chemoradiotherapy regimen after 22Gy and one cycle of 5-fluorouracil-cisplatinum. He was treated for a cervical squamous cell lymph node of unknown origin. Grade 3 mucitis and epitheliitis were observed only in the irradiated fields and required the end of the radiotherapy. Tuberous sclerosis is characterized by a loss of the TSC2 function, with a permanent activation of the mTOR pathway. Logically, some kind of "radioresistance" should be observed. Increased radiosensitivity is paradoxical. This case illustrates how radiosensitivity is a complex phenomenon and clinically unpredictable. Efficiency of the protocols associations of mTOR inhibitors and radiotherapy should be carefully scrutinized.
Copyright © 2012 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23270679     DOI: 10.1016/j.canrad.2012.11.001

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Radiobiological Characterization of Tuberous Sclerosis: a Delay in the Nucleo-Shuttling of ATM May Be Responsible for Radiosensitivity.

Authors:  Mélanie L Ferlazzo; Mohamed Kheir Eddine Bach-Tobdji; Amar Djerad; Laurène Sonzogni; Clément Devic; Adeline Granzotto; Larry Bodgi; Jean-Thomas Bachelet; Assia Djefal-Kerrar; Christophe Hennequin; Nicolas Foray
Journal:  Mol Neurobiol       Date:  2017-08-07       Impact factor: 5.590

2.  Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.

Authors:  Carleen Cullinane; Kelly Waldeck; Laura Kirby; Buck E Rogers; Peter Eu; Richard W Tothill; Rodney J Hicks
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.